Sept 27 (Reuters) - Helix Biopharma Corp HBP.TO
* Helix Biopharma Corp. Announces fda approval to accelerate dose escalation for U.S. Phase i clinical study
* Helix Biopharma Corp- U.S. Food and drug administration has approved an amendment to their U.S. Phase I study, protocol ldos001
* Helix Biopharma - study to implement accelerated dose design up to 6g/kg followed by standard 3+3 design for final 2 dosing cohorts, 9 and 12 g/kg